PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of pharmscispringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSci. 2004 March; 6(1): 86–93.
Published online 2015 July 10. doi:  10.1208/ps060109
PMCID: PMC2750944

Pharmacokinetic model of target-mediated disposition of thrombopoietin

Abstract

Thrombopoietin, TPO, a 353 amino acid cytokine, is a primary regulator of platelet production that was cloned recently. A target-mediated (platelet receptors) pharmacokinetic model was developed to characterize the disposition of TPO. Receptor-mediated endocytosis was assigned as the major elimination pathway in the model. A nonspecific binding compartment was also incorporated into the model. TPO concentration vs time profiles from a published phase 1 and 2 clinical trial were used to apply this model. Noncompartmental analysis demonstrated that TPO exhibits nonlinear kinetics. The proposed model captured the concentration-time profiles relatively well. The first-order internalization rate constant was estimated as 0.1 h−1. The endogenous binding capacity was estimated as 164.0 pM. The second-order binding association constant (kon) was 0.055 h−1·pM−1 and the first-order dissociation constant (koff) was estimated as 2.5 h−1, rendering the equilibrium dissociation constant Kd as 45.5 pM. This model may be relevant to other therapeutic agents with receptor-mediated endocytotic disposition.

Keywords: thrombopoietin, receptor-mediated drug disposition, pharmacodynamic model

References

1. Bartley TD, Bogenberger J, Hunt P, Li YS, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor. Mpl. Cell. 1994;77:1117–1124. doi: 10.1016/0092-8674(94)90450-2. [PubMed] [Cross Ref]
2. Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369:533–538. doi: 10.1038/369533a0. [PubMed] [Cross Ref]
3. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A. 1994;91:11104–11108. doi: 10.1073/pnas.91.23.11104. [PubMed] [Cross Ref]
4. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine TPO cDNA and stimulation of platelet production in vivo. Nature. 1994;369:565–568. doi: 10.1038/369565a0. [PubMed] [Cross Ref]
5. Sohma Y, Akahori H, Seki N, et al. Molecular cloning and chromosomal localization of the human TPO gene. FEBS Lett. 1994;353:57–61. doi: 10.1016/0014-5793(94)01008-0. [PubMed] [Cross Ref]
6. Vigon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A. 1992;89:5640–5644. doi: 10.1073/pnas.89.12.5640. [PubMed] [Cross Ref]
7. Debili N, Wendling F, Cosman D, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood. 1995;85:391–401. [PubMed]
8. Kaushansky K, Broudy VC, Lin N, et al. TPO, the Mp1 ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci U S A. 1995;92:3234–3238. doi: 10.1073/pnas.92.8.3234. [PubMed] [Cross Ref]
9. Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M. Recombinant human TPO (Mpl ligand) enhances proliferation of erythroid progenitors. Blood. 1995;86:2494–2499. [PubMed]
10. Simicka E, Lin N, Priestley GV, et al. The effect of TPO on the proliferation and differentiation of murine hematopoietic stem cells. Blood. 1996;87:4998–5005. [PubMed]
11. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand TPO. Nature. 1994;369:568–571. doi: 10.1038/369568a0. [PubMed] [Cross Ref]
12. Hokom MM, Lacey D, Kinstler OB, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood. 1995;86:4486–4492. [PubMed]
13. Cardier JE, Dempsey J. TPO and its receptor, c-mpl, are constitutively expressed by mouse liver endothelial cells: evidence of TPO as a growth factor for liver endothelial cells. Blood. 1998;91:923–929. [PubMed]
14. Sungaran R, Markovic B, Chong BH. Localization and regulation of TPO mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood. 1997;89:101–107. [PubMed]
15. Kuter DJ, Rosenberg RD. The reciprocal relationship of TPO (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood. 1995;85:2720–2730. [PubMed]
16. Bondurant MC, Koury MJ. Anemia induces accumulation of erythropoietin mRNA in the kidney and liver. Mol Cell Biol. 1986;6:2731–2733. doi: 10.1128/MCB.6.7.2731. [PMC free article] [PubMed] [Cross Ref]
17. Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of TPO levels by c-mpl-mediated binding to platelets. Blood. 1996;87:2154–2161. [PubMed]
18. Sugiyama Y, Hanano M. Receptor-mediated transport of peptide hormones and its importance in the overall homone disposition in the body. Pharm Res. 1989;6:192–202. doi: 10.1023/A:1015905331391. [PubMed] [Cross Ref]
19. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507–532. doi: 10.1023/A:1014414520282. [PubMed] [Cross Ref]
20. Fielder PJ, Hass P, Nagel M, et al. Human platelets as a model for the binding and degradation of TPO. Blood. 1997;89:2782–2788. [PubMed]
21. Li J, Xia Y, Kuter DJ. Interaction of TPO with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999;106:345–356. doi: 10.1046/j.1365-2141.1999.01571.x. [PubMed] [Cross Ref]
22. Broudy VC, Lin NL, Sabath DF, Papayannopoulou T, Kaushansky K. Human platelets display high-affinity receptors for TPO. Blood. 1997;89:1896–1904. [PubMed]
23. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human TPO in patients with cancer. Ann Intern Med. 1997;126:673–681. doi: 10.7326/0003-4819-126-9-199705010-00001. [PubMed] [Cross Ref]
24. D Argenio DZ, Schumitzky A. ADAPT II Users Guide. Los Angeles, CA: Biomedical Simulations Resource; 1997.
25. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994;56:248–252. doi: 10.1038/clpt.1994.134. [PubMed] [Cross Ref]
26. Kuter DJ. TPOs and thrombopoiesis: a clinical perspective. Vox Sang. 1998;74:75–85. doi: 10.1111/j.1423-0410.1998.tb05400.x. [PubMed] [Cross Ref]
27. Braeckman R. Pharmacokinetics and pharmacodynamics of protein therapeutics. In: Reid RE, editor. Peptide and Protein Drug Analysis. New York, NY: Marcel Dekker; 2000. pp. 633–669.
28. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993;21:457–478. doi: 10.1007/BF01061691. [PMC free article] [PubMed] [Cross Ref]
29. Krzyzanski W, Ramakrishnan R, Jusko WJ. Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm. 1999;27:467–489. doi: 10.1023/A:1023249813106. [PubMed] [Cross Ref]
30. Ruka W, Rutkowski P, Kaminska J, Rysinska A, Steffen J. Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationship to cytokine serum levels and prognostic significance. Ann Oncol. 2001;12:1423–1432. doi: 10.1023/A:1012527006566. [PubMed] [Cross Ref]
31. Emmons RV, Reid DM, Cohen RL, et al. Human TPO levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87:4068–4071. [PubMed]
32. Rowland M, Tozer TN, Rowland R. Clinical Pharmacokinetics: Concepts and Applications. Philadelphia, PA: Lippincott, Williams & Wilkins; 1995.
33. Cheng HY, Jusko WJ. Mean residence time concepts for pharmacokinetic systems with nonlinear drug elimination described by the Michaelis-Menten equation. Pharm Res. 1988;5:156–164. doi: 10.1023/A:1015960806202. [PubMed] [Cross Ref]
34. Jusko WJ. Pharmacokinetics of capacity-limited systems. J Clin Pharmacol. 1989;29:488–493. doi: 10.1002/j.1552-4604.1989.tb03369.x. [PubMed] [Cross Ref]
35. Lin JH. Dose-dependent pharmacokinetics: experimental observations and theoretical considerations. Biopharm Drug Dispos. 1994;15:1–31. doi: 10.1002/bdd.2510150102. [PubMed] [Cross Ref]

Articles from AAPS PharmSci are provided here courtesy of American Association of Pharmaceutical Scientists